Definium Therapeutics, Inc. (NASDAQ:DFTX) Stock Has Average Price Target of $64.88

Definium Therapeutics, Inc. (NASDAQ:DFTX) has earned a consensus rating of “Buy” from the twenty-one ratings firms that are presently covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating, eighteen have assigned a buy rating and two have assigned a strong buy rating to the company. The average 1 year price target among analysts that have covered the stock in the last year is $64.88.

Several equities research analysts recently issued reports on DFTX shares. Robert W. Baird raised their target price on shares of Definium Therapeutics from $75.00 to $79.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 15th. Stifel Nicolaus upped their price target on shares of Definium Therapeutics from $30.00 to $60.00 and gave the stock a “buy” rating in a research report on Wednesday, July 8th. Oppenheimer reaffirmed an “outperform” rating and set a $75.00 price target on shares of Definium Therapeutics in a research note on Monday, September 14th. Canaccord Genuity Group set a $78.00 price target on shares of Definium Therapeutics and gave the company a “buy” rating in a report on Tuesday, September 15th. Finally, Bank of America assumed coverage on shares of Definium Therapeutics in a research note on Tuesday, August 18th. They set a “buy” rating and a $75.00 price objective for the company.

Definium Therapeutics Stock Performance

NASDAQ DFTX opened at $38.21 on Friday. The business’s 50-day moving average price is $41.37 and its 200 day moving average price is $32.06. The company has a current ratio of 6.95, a quick ratio of 6.95 and a debt-to-equity ratio of 0.04. Definium Therapeutics has a twelve month low of $10.46 and a twelve month high of $49.70. The company has a market capitalization of $5.13 billion, a PE ratio of -11.14 and a beta of 2.23.

Definium Therapeutics (NASDAQ:DFTX) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($1.44) EPS for the quarter, missing the consensus estimate of ($0.55) by ($0.89). On average, research analysts predict that Definium Therapeutics will post -3.02 earnings per share for the current year.

Definium Therapeutics News Summary

Here are the key news stories impacting Definium Therapeutics this week:

• Positive Sentiment: Definium granted stock options covering 334,810 shares to 15 newly hired non-executive employees. The hiring supports the company’s efforts to advance its pipeline of psychiatric and neurological therapies and expand its workforce. Definium Therapeutics Announces New Employee Inducement Grants
• Neutral Sentiment: The employee options may help attract and retain talent, but they also represent potential share dilution. The grants were inducement awards for new employees rather than a change to the company’s operating outlook.
• Negative Sentiment: Four insiders collectively sold 52,075 shares for approximately $1.90 million at an average price of $36.57. The sales included CEO Robert Barrow’s 31,550 shares, insider Mark Sullivan’s 14,051 shares, CFO Brandi Roberts’ 3,377 shares and Matthew Wiley’s 3,097 shares. Such concentrated selling can pressure sentiment and raise concerns about insider confidence, even though each seller retained a substantial position.
• Negative Sentiment: All four transactions were executed under pre-arranged Rule 10b5-1 trading plans, which reduces their significance as discretionary bearish signals but does not eliminate the near-term perception of increased insider selling.

Insider Transactions at Definium Therapeutics

In related news, CEO Robert Barrow sold 31,550 shares of Definium Therapeutics stock in a transaction on Friday, September 25th. The stock was sold at an average price of $36.57, for a total value of $1,153,783.50. Following the transaction, the chief executive officer owned 2,213,090 shares in the company, valued at approximately $80,932,701.30. This trade represents a 1.41% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Matthew Wiley sold 3,097 shares of the business’s stock in a transaction dated Friday, September 25th. The shares were sold at an average price of $36.57, for a total value of $113,257.29. Following the sale, the insider directly owned 359,036 shares of the company’s stock, valued at approximately $13,129,946.52. This trade represents a 0.86% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 71,098 shares of company stock worth $2,626,115 over the last ninety days. 2.40% of the stock is owned by insiders.

Institutional Trading of Definium Therapeutics

A number of institutional investors have recently modified their holdings of DFTX. Avoro Capital Advisors LLC acquired a new position in shares of Definium Therapeutics during the fourth quarter worth about $66,950,000. Wellington Management Group LLP purchased a new stake in shares of Definium Therapeutics in the second quarter worth about $138,755,000. Seven Fleet Capital Management LP acquired a new stake in shares of Definium Therapeutics in the second quarter valued at about $6,992,000. Royce & Associates LP grew its stake in shares of Definium Therapeutics by 102.5% in the fourth quarter. Royce & Associates LP now owns 164,041 shares of the company’s stock valued at $2,197,000 after buying an additional 83,017 shares in the last quarter. Finally, Platinum Investment Management Ltd. purchased a new stake in shares of Definium Therapeutics during the 4th quarter valued at about $937,000. Hedge funds and other institutional investors own 27.91% of the company’s stock.

Definium Therapeutics Company Profile

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.